A Double-Blinded, Randomized Placebo Controlled Pilot Study Comparing the Efficacy and Safety of IncobotulinumtoxinA Versus Saline Injections to the Cheek Region in Patients With Rosacea
Overview
- Phase
- Phase 2
- Intervention
- IncobotulinumtoxinA
- Conditions
- Rosacea
- Sponsor
- DeNova Research
- Enrollment
- 9
- Locations
- 1
- Primary Endpoint
- Percent Change From Baseline in the Rosacea Clinical Score Card
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
This is a double-blinded, randomized placebo controlled pilot study comparing the efficacy and safety of incobotulinumtoxinA versus saline injections to the cheek region in patients with rosacea.
The pilot study will enroll and treat a total of 10 subjects who present with rosacea of the cheek area. Upon study entry, subjects will be randomized to receive treatment with incobotulinumtoxinA or bacteriostatic saline to the cheek area. Study treatment will be prepared by an unblinded designee and both Physician Investigator (PI) and subject will remain blinded for the duration of the study. At the 16 week visit, control subjects will enter the rescue arm portion of the study and all study subjects will receive treatment with incobotulinumtoxinA to the cheek areas.
Investigators
Steven H. Dayan
Medical Director
DeNova Research
Eligibility Criteria
Inclusion Criteria
- •Males and females between 18 and 65 years of age.
- •Subjects presenting with rosacea in the cheek area.
- •Willingness and ability to comply with protocol requirements, including returning for follow-up visits and abstaining from exclusionary procedures for the duration of the study.
- •Subjects of childbearing potential must have a negative urine pregnancy test result at Visit 1 and be willing able to use an acceptable method of birth control (e.g., barrier methods used with a spermicidal agent, hormonal methods, IUD, surgical sterilization, abstinence) during the study. Women will not be considered of childbearing potential if one of the following is documented on the medical history:
- •postmenopausal for at least 12 months prior to study drug administration
- •without a uterus and/or both ovaries
- •has had a bilateral tubal ligation for at least 6 months prior to study drug administration.
- •absence of an other physical condition according to the PI's discretion
- •Willingness and ability to provide written photo consent and adherence to photography procedures (i.e., removal of jewelry and makeup).
- •Willingness and ability to provide written informed consent prior to performance of any study related procedure.
Exclusion Criteria
- •Subjects who are pregnant, nursing, planning to become pregnant, and/or not using a reliable form of birth control.
- •Subjects with a known allergy or sensitivity to any component of the study medications or anesthesia.
- •Topical or oral rosacea treatments within the past 2 weeks.
- •Subjects with a significant systemic illness or illness localized to the areas of treatment.
- •Botulinum toxin to the face within the past 6 months.
- •Significant concurrent illness such as diabetes, epilepsy, lupus, or congestive heart failure.
- •Concurrent skin condition affecting area to be treated.
- •Prior surgery on the area to be treated within 3 months of initial treatment or during the study.
- •History or evidence of keloids or hypertrophic scarring.
- •Subjects currently using aminoglycoside antibiotics, curare-like agents or other agents that might interfere with neuromuscular function.
Arms & Interventions
IncobotulinumtoxinA
Intervention: IncobotulinumtoxinA
Placebo
Intervention: Bacteriostatic saline
Outcomes
Primary Outcomes
Percent Change From Baseline in the Rosacea Clinical Score Card
Time Frame: baseline, 1 week, 4 weeks, 12 weeks, 16 weeks, 17 weeks and 20 weeks
Live rosacea assessment for each side of the face using the Rosacea Clinical Scorecard for clinical assessment.The Rosacea Clinical Scorecard assesses the primary signs and symptoms of rosacea and is graded as absent (0), mild (1), moderate (2) or severe (3).
Number of Participants Experiencing Adverse Events
Time Frame: baseline, 1 week, 4 weeks, 12 weeks, 16 weeks, 17 weeks and 20 weeks
Rate of adverse events
Secondary Outcomes
- Mean Heatherton & Polivy State Self-Esteem (HPSS) Scale Score at Baseline, 1, 4, 12, 16, 17, and 20 Weeks(baseline, 1 week, 4 weeks, 12 weeks, 16 weeks, 17 weeks and 20 weeks)
- Patient Satisfaction(week 1, 4 weeks, 12 weeks, 16 weeks, 17 weeks and 20 weeks)